Skip to content

DBS for Home Monitoring in Children With Kidney Transplantation

Novel Use of Dried Blood Spots (DBS)for Home Monitoring in Children With Kidney

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01931397
Acronym
DBS
Enrollment
30
Registered
2013-08-29
Start date
2013-07-31
Completion date
2015-02-28
Last updated
2017-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Keywords

Dried blood spots, kidney transplant, Children

Brief summary

Kidney transplantation is the treatment of choice for kidney failure in children. Kidney transplant recipients need to take immunosuppression for the rest of their lives after transplantation to prevent rejection of the graft. One of the important medications is called Tacrolimus which can prevent rejection of the kidney graft but at the same time is toxic to the kidney. Therefore, repeated blood levels of Tacrolimus with tests of kidney function will help physicians to prescribe the best dose for therapy to prevent kidney rejection and kidney toxicity. Failure of compliance with taking Tacrolimus is also an important cause of graft failure especially among teenagers, so repeated blood Tacrolimus levels are necessary to detect patients who fail to take their medications on a regular basis. We have developed a lab assay that measures Tacrolimus blood level and creatinine (for kidney function) using one dried blood spot (DBS) on filter paper similar to the filter paper used in the new born screen. We plan to teach patients how to do the test at home once a month and mail the filter paper back to OHSU for analysis for Tacrolimus and creatinine. The advantage of this method is that it is less painful for children then a regular blood dray from the vein, can be done easily at home, will be most cost effective as it will save the family a day of work or school and can detect both the Tacrolimus level and the kidney function at the same time. We will assess the effect of doing this simple finger prick at home on compliance, on Tacrolimus levels and kidney function over the study period of one year. We will also assess how satisfied patients are with this method instead of going to the lab or the hospital for blood test. All subjects will continue on their regular clinic visits and will continue to have their routine blood draws by intravenous method in the lab during the study.

Detailed description

Specific Aim 1: To validate the DBS method as a home monitoring device for use at home by parents and patients in 30 pediatric kidney transplant recipients. We will validate the TAC and creatinine (Cr) blood levels obtained by DBS method in comparison to blood TAC and serum creatinine levels using standard laboratory assays in CLIA approved clinical laboratories. Specific Aim 2: The use of DBS on filter papers is associated with better adherence to monthly blood testing and medication intake. This aim can be tested by assessing the number of DBS on filter papers that are returned to OHSU every month. Adherence with medication intake will be assessed by measuring the variability of TAC trough levels, and by individual reporting. We will calculate the percent of returned DBS filter papers to OHSU on a monthly basis as well as the percent of those that are collected properly at home and are successfully utilized for TAC and Cr analysis. Specific Aim 3: This aim will explore patient and family satisfaction and self management using DBS method vs. the standard method of scheduled clinic and laboratory visits. Design: This is a pilot study to evaluate and validate the novel use of DBS on filter paper as a home monitoring method. This study will involve within-subjects, repeated measures design to test specific hypotheses. Participants: The pediatric kidney transplant program at Doernbecher Children's Hospital/OHSU follows approximately 120 active renal transplant recipients between 2-21 years. Thirty patients of both genders will participate in this study and will be followed for one year. Inclusion criteria: 1. On Tacrolimus immunosuppression therapy 2. At least six months post kidney transplantation

Interventions

None listed

Sponsors

Astellas Pharma US, Inc.
CollaboratorINDUSTRY
Oregon Health and Science University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

Kidney transplant recipients between the ages of 2-21 years at time of enrollment 1. On Tacrolimus immunosuppression therapy 2. At least six months post kidney transplantation

Exclusion criteria

Not on tacrolimus therapy Less than 6 months after kidney transplantation Refusal to provide consent fomr

Design outcomes

Primary

MeasureTime frameDescription
Variability of Tacrolimus Blood Levels Measured by DBS Over Time12 monthsMean standard deviation scores for Tacrolimus blood levels obtained by DBS for each patient over time.

Secondary

MeasureTime frameDescription
Percentage of Families Preferring DBS MethodAt baseline and then at 12 monthsThe % of families who anticipated preference of DBS method over intravenous blood draws at the time of enrollment and then the % of those who preferred DBS at end of study period (12 months). Families include parents/caregivers and participants who are over 10 years of age were asked to fill in the preference scale separately. Preference for DBS Testing was measured using a Visual Analog Scale (VAS) on which a zero was equivalent to no preference for DBS versus laboratory-based monitoring and on which positive numbers indicated greater preference for DBS (up to +72) and negative scores indicated a greater preference for laboratory-based monitoring (down to -72).

Other

MeasureTime frameDescription
Mean Tacrolimus Blood Levels Measured by DBS Over Study Period According to Ageup to 12 monthsMean Tacrolimus blood levels obtained by DBS in each patient over their time in the study in children who are 12 years and over versus those less than 12 years of age.
Changes in Adherence Parameters to Home DBS MethodAt baseline then every 3 months for 12 monthsWe will calculate the percent of returned DBS filter papers to OHSU on a monthly basis utilized for TAC and Cr analysis. we calculated the percentage as the number of DBS that were actually received divided by the total number of DBS expected to be received from participants over the study time period

Countries

United States

Participant flow

Participants by arm

ArmCount
Total Cohort
This is a prospective non randomized study. All patients were approached at the pediatric kidney transplant clinic at OHSU in a non randomized fashion until the target enrollment of 30 patients was met.
30
Total30

Withdrawals & dropouts

PeriodReasonFG000
Overall Studymoved out of state1
Overall StudyPhysician Decision2
Overall StudyWithdrawal by Subject8

Baseline characteristics

CharacteristicTotal Cohort
Age, Continuous13.6 years
STANDARD_DEVIATION 5.4
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
26 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Number of years post kidney transplantation5.93 years
STANDARD_DEVIATION 4.57
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
26 Participants
Region of Enrollment
United States
30 participants
Sex: Female, Male
Female
12 Participants
Sex: Female, Male
Male
18 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 30
serious
Total, serious adverse events
0 / 30

Outcome results

Primary

Variability of Tacrolimus Blood Levels Measured by DBS Over Time

Mean standard deviation scores for Tacrolimus blood levels obtained by DBS for each patient over time.

Time frame: 12 months

Population: 9 participants were excluded from final analysis because they submitted two or less evaluable blood samples. A total of 216 DBS samples were received during the study

ArmMeasureValue (MEAN)Dispersion
Total CohortVariability of Tacrolimus Blood Levels Measured by DBS Over Time2.635 ng/mlStandard Deviation 1.086
Secondary

Percentage of Families Preferring DBS Method

The % of families who anticipated preference of DBS method over intravenous blood draws at the time of enrollment and then the % of those who preferred DBS at end of study period (12 months). Families include parents/caregivers and participants who are over 10 years of age were asked to fill in the preference scale separately. Preference for DBS Testing was measured using a Visual Analog Scale (VAS) on which a zero was equivalent to no preference for DBS versus laboratory-based monitoring and on which positive numbers indicated greater preference for DBS (up to +72) and negative scores indicated a greater preference for laboratory-based monitoring (down to -72).

Time frame: At baseline and then at 12 months

Population: 25 families participated in the preference survey at time of enrollment and only 15 families completed the survey at the end of the study period (12 months).

ArmMeasureValue (NUMBER)
Total CohortPercentage of Families Preferring DBS Method88 % of families
At End of StudyPercentage of Families Preferring DBS Method93 % of families
Other Pre-specified

Changes in Adherence Parameters to Home DBS Method

We will calculate the percent of returned DBS filter papers to OHSU on a monthly basis utilized for TAC and Cr analysis. we calculated the percentage as the number of DBS that were actually received divided by the total number of DBS expected to be received from participants over the study time period

Time frame: At baseline then every 3 months for 12 months

Population: The number of DBS cards expected to be received by those 28 patients were 279 DBS samples.

ArmMeasureValue (NUMBER)
Total CohortChanges in Adherence Parameters to Home DBS Method77 percentage of DBS cards
Other Pre-specified

Mean Tacrolimus Blood Levels Measured by DBS Over Study Period According to Age

Mean Tacrolimus blood levels obtained by DBS in each patient over their time in the study in children who are 12 years and over versus those less than 12 years of age.

Time frame: up to 12 months

Population: We analyzed a total of 216 dried blood spots for Tacrolimus blood levels measured in ng/ml

ArmMeasureValue (MEAN)Dispersion
Total CohortMean Tacrolimus Blood Levels Measured by DBS Over Study Period According to Age2.73 ng/mlStandard Deviation 1.21
At End of StudyMean Tacrolimus Blood Levels Measured by DBS Over Study Period According to Age2.81 ng/mlStandard Deviation 1.16

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026